CO6430428A2 - Composiciones, síntesis, y métodos de utilización de derivados de arilopiperazina - Google Patents

Composiciones, síntesis, y métodos de utilización de derivados de arilopiperazina

Info

Publication number
CO6430428A2
CO6430428A2 CO11121527A CO11121527A CO6430428A2 CO 6430428 A2 CO6430428 A2 CO 6430428A2 CO 11121527 A CO11121527 A CO 11121527A CO 11121527 A CO11121527 A CO 11121527A CO 6430428 A2 CO6430428 A2 CO 6430428A2
Authority
CO
Colombia
Prior art keywords
synthesis
compounds
methods
compositions
arylopiperazine
Prior art date
Application number
CO11121527A
Other languages
English (en)
Inventor
Lasminarayan Bhat
Prabhu Prasad Mohapatra
Kouacou Adiey
Original Assignee
Reviva Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reviva Pharmaceuticals Inc filed Critical Reviva Pharmaceuticals Inc
Publication of CO6430428A2 publication Critical patent/CO6430428A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Abstract

La invención actual proporciona compuestos, síntesis de los compuestos, composiciones y métodos de utilización de los compuestos para el tratamiento de la esquizofrenia y psicosis relacionadas tales como manía aguda, trastorno bipolar, autismo y depresión, donde los compuestos son derivados de arilopiperazina. La actual invención proporciona métodos para la síntesis de estos compuestos de arilopiperazina. La invención actual también proporciona métodos para el uso de antipsicóticos atípicos a base de arilopiperazina, y la composición de antipsicóticos atípicos a base de arilopiperazina para el tratamiento de la esquizofrenia y psicosis relacionadas tales como manías agudas, trastorno bipolar, autismo y depresión.
CO11121527A 2009-02-26 2011-09-19 Composiciones, síntesis, y métodos de utilización de derivados de arilopiperazina CO6430428A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15579109P 2009-02-26 2009-02-26

Publications (1)

Publication Number Publication Date
CO6430428A2 true CO6430428A2 (es) 2012-04-30

Family

ID=42631516

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11121527A CO6430428A2 (es) 2009-02-26 2011-09-19 Composiciones, síntesis, y métodos de utilización de derivados de arilopiperazina

Country Status (25)

Country Link
US (9) US8575185B2 (es)
EP (1) EP2400968B1 (es)
JP (1) JP5337259B2 (es)
KR (1) KR101705727B1 (es)
CN (2) CN106045936A (es)
AU (1) AU2010217772B2 (es)
BR (1) BRPI1009757B1 (es)
CA (1) CA2753599C (es)
CO (1) CO6430428A2 (es)
DK (1) DK2400968T3 (es)
ES (1) ES2605232T3 (es)
HK (1) HK1167240A1 (es)
HU (1) HUE031053T2 (es)
IL (1) IL214754A (es)
MX (1) MX2011008885A (es)
MY (1) MY161473A (es)
NZ (1) NZ595263A (es)
PH (1) PH12011501669B1 (es)
PL (1) PL2400968T3 (es)
PT (1) PT2400968T (es)
RU (1) RU2506262C2 (es)
SG (1) SG173842A1 (es)
UA (1) UA102730C2 (es)
WO (2) WO2010099502A1 (es)
ZA (1) ZA201106805B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010099502A1 (en) 2009-02-26 2010-09-02 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of utilizing arylpiperazine derivatives
KR101571670B1 (ko) * 2012-08-08 2015-11-25 주식회사 씨엠지제약 아리피프라졸을 포함하는 경구용 속용 필름 제제
WO2015157451A1 (en) 2014-04-08 2015-10-15 Reviva Pharmaceuticals, Inc. Methods for treating attention deficit hyperactivity disorder
CN107206007B (zh) * 2015-01-12 2021-08-10 雷维瓦药品公司 用于治疗肺高血压的方法
WO2016115150A1 (en) * 2015-01-12 2016-07-21 Reviva Pharmaceuticals Inc. Methods for treating psychosis associated with parkinson's disease
WO2016115144A1 (en) 2015-01-12 2016-07-21 Reviva Pharmaceuticals Inc. Methods for treating alzheimer's disease
GB201508864D0 (en) * 2015-05-22 2015-07-01 Glaxosmithkline Ip Dev Ltd Compounds
WO2017042837A2 (en) * 2015-09-11 2017-03-16 Sun Pharmaceutical Industries Limited Stable crystalline form of regadenoson
CN113912586B (zh) 2016-08-31 2023-04-07 江苏恒瑞医药股份有限公司 氧代吡啶酰胺类衍生物、其制备方法及其在医药上的应用
CN112618580A (zh) * 2020-12-30 2021-04-09 北京科拓恒通生物技术股份有限公司 鼠李糖乳杆菌Probio-M9及其制品用于制备治疗自闭症药物的用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274194A (en) 1963-03-29 1966-09-20 Miles Lab Quinazolinedione derivatives
FR2035749A1 (es) * 1969-02-06 1970-12-24 Bellon Labor Sa Roger
US3726979A (en) 1971-04-09 1973-04-10 E Hong Method of producing serotonin antagonism
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3879393A (en) 1973-06-18 1975-04-22 Miles Lab Derivatives of 1,3-disubstituted 2,4(1h,3h)-quinazolinediones
PH17194A (en) 1980-03-06 1984-06-19 Otsuka Pharma Co Ltd Novel carbostyril derivatives,and pharmaceutical composition containing the same
JPS58159480A (ja) 1982-03-17 1983-09-21 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
JPS5970675A (ja) * 1982-10-15 1984-04-21 Otsuka Pharmaceut Co Ltd ベンゾオキサジン誘導体
JPS60169467A (ja) 1984-02-10 1985-09-02 Chugai Pharmaceut Co Ltd 新規なフエニルピペラジン誘導体
US4613598A (en) * 1984-03-13 1986-09-23 Mitsubishi Chemical Industries Limited Piperazine derivatives and their acid addition salts
US4716161A (en) 1984-04-17 1987-12-29 Mitsubishi Chemical Industries Limited Phenylpiperazine derivatives and their acid addition salts
US4711883A (en) 1985-09-30 1987-12-08 Ortho Pharmaceutical Corporation Substituted 3-(4-phenyl-1-piperazinyl)alkylquinazolin-2,4-(1H,3H) diones, methods of preparation, compositions and method of use
DK588486A (da) * 1985-12-09 1987-06-10 Otsuka Pharma Co Ltd Anvendelse af en forbindelse til behandling af hypoxi
US4803203A (en) 1986-11-05 1989-02-07 Warner-Lambert Company Phenyl and heterocyclic piperazinyl alkoxy-benzheterocyclic compounds as antipsychotic agents
FR2618437B1 (fr) 1987-07-23 1989-11-17 Rhone Poulenc Sante Nouveaux derives du benzopyranne, leur preparation et les medicaments qui les contiennent
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
DK203990D0 (da) 1990-08-24 1990-08-24 Novo Nordisk As Piperazinylderivater
US5234924A (en) * 1990-09-26 1993-08-10 Adir Et Compagnie Benzothiazine and benzothiazole compounds useful as analgesics
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
FR2680172B1 (fr) 1991-08-05 1993-11-19 Fabre Medicament Pierre Nouvelles piperazinylalcoyl-3 dihydro-2,3 4h-benzoxazine-1,3 ones-4 substituees, leur preparation et leur application en therapeutique.
JPH05331151A (ja) 1992-05-28 1993-12-14 Kyowa Hakko Kogyo Co Ltd キノキサリン−２−オン誘導体
US5994542A (en) 1995-11-14 1999-11-30 Sumitomo Chemical Company, Limited Process for producing 1-substituted tetrahydroquinazolines
FR2755690B1 (fr) 1996-11-08 1998-12-18 Adir Nouveaux derives aminomethyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19743435A1 (de) 1997-10-01 1999-04-08 Merck Patent Gmbh Benzamidinderivate
SE0200301D0 (sv) * 2002-02-01 2002-02-01 Axon Biochemicals Bv Thio-carbostyril derivative
AU2003288755C1 (en) 2003-01-09 2015-02-19 Otsuka Pharmaceutical Co., Ltd. Process for preparing aripiprazole
CA2428237C (en) 2003-05-08 2010-07-20 Delmar Chemicals Inc. Process for the preparation of carbostyril derivatives
CN102000336A (zh) 2003-05-23 2011-04-06 大塚制药株式会社 用于治疗情感障碍的喹诺酮衍生物和情绪稳定剂
US7160888B2 (en) * 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
WO2005092841A1 (en) * 2004-03-23 2005-10-06 Pfizer Limited Compounds having beta-agonist activity
US7253168B2 (en) 2004-04-07 2007-08-07 Neurogen Corporation Substituted 1-benzyl-4-substituted piperazine analogues
US20090198059A1 (en) 2004-09-13 2009-08-06 Chava Satyanarayana Process for the preparation of polymorphs, solvates of aripiprazole using aripirazole acid salts
JP2007137818A (ja) 2005-11-17 2007-06-07 Taisho Pharmaceut Co Ltd ８−ヒドロキシ−２，４（１ｈ，３ｈ）−キナゾリンジオン誘導体
WO2008024481A2 (en) * 2006-08-24 2008-02-28 Concert Pharmaceuticals Inc. 3,4-dihydro-2 (1h) - quinolinone and 2 (1h)-quinolinone derivatives
JP4785881B2 (ja) * 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
NZ582124A (en) * 2007-05-21 2012-07-27 Reviva Pharmaceuticals Inc Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2234555B1 (en) * 2008-01-25 2016-01-06 Medtronic ATS Medical, Inc. Cryoprobe clamp having transmurality assessment window
WO2009154993A1 (en) * 2008-05-27 2009-12-23 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using piperazine based antipsychotic agents
WO2010099502A1 (en) * 2009-02-26 2010-09-02 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of utilizing arylpiperazine derivatives
JP5331151B2 (ja) 2011-03-30 2013-10-30 日本発條株式会社 車両用シート

Also Published As

Publication number Publication date
NZ595263A (en) 2013-06-28
US20150005298A1 (en) 2015-01-01
US8431570B2 (en) 2013-04-30
US20100216783A1 (en) 2010-08-26
US20160229821A1 (en) 2016-08-11
US8188076B2 (en) 2012-05-29
EP2400968B1 (en) 2016-09-28
BRPI1009757A2 (pt) 2016-03-15
EP2400968A1 (en) 2012-01-04
EP2400968A4 (en) 2012-08-01
US8461154B2 (en) 2013-06-11
US8575185B2 (en) 2013-11-05
ES2605232T3 (es) 2017-03-13
AU2010217772A1 (en) 2011-10-20
US20150166493A1 (en) 2015-06-18
US8859552B2 (en) 2014-10-14
PT2400968T (pt) 2016-12-09
RU2506262C2 (ru) 2014-02-10
IL214754A0 (en) 2011-11-30
US9975862B2 (en) 2018-05-22
IL214754A (en) 2014-05-28
BRPI1009757B1 (pt) 2020-01-14
HUE031053T2 (en) 2017-06-28
US20100222359A1 (en) 2010-09-02
JP5337259B2 (ja) 2013-11-06
CN102413830A (zh) 2012-04-11
DK2400968T3 (da) 2017-01-02
PH12011501669B1 (en) 2014-02-13
HK1167240A1 (zh) 2012-11-23
KR20120013306A (ko) 2012-02-14
CA2753599C (en) 2017-03-14
KR101705727B1 (ko) 2017-02-10
AU2010217772B2 (en) 2014-10-23
MX2011008885A (es) 2011-09-29
CA2753599A1 (en) 2010-09-02
JP2012519182A (ja) 2012-08-23
WO2010099503A1 (en) 2010-09-02
US20120220574A1 (en) 2012-08-30
US9604944B2 (en) 2017-03-28
US8980883B2 (en) 2015-03-17
WO2010099502A1 (en) 2010-09-02
US20140155392A1 (en) 2014-06-05
MY161473A (en) 2017-04-14
US20120220579A1 (en) 2012-08-30
RU2011139154A (ru) 2013-04-10
ZA201106805B (en) 2013-02-27
UA102730C2 (uk) 2013-08-12
PL2400968T3 (pl) 2017-04-28
CN106045936A (zh) 2016-10-26
SG173842A1 (en) 2011-09-29
US20170327477A1 (en) 2017-11-16
US9255076B2 (en) 2016-02-09

Similar Documents

Publication Publication Date Title
CO6430428A2 (es) Composiciones, síntesis, y métodos de utilización de derivados de arilopiperazina
ECSP14013264A (es) Nuevos derivados bicíclicos de dihidroquinolina-2-ona
UY32863A (es) COMPUESTOS DE HEXAHIDROOXAZINOPTERINA PARA USO COMO INHIBIDORES DE mTOR
PH12014502697B1 (en) New diazaspirocycloalkane and azaspirocycloalkane
CR11827A (es) Activadores de glucoquinasa
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
CL2017002452A1 (es) Nuevos compuestos bicíclicos
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
MX368615B (es) Derivados bicíclicos como inhibidores de la autotaxina (atx) que son inhibidores de la producción de ácido lisofosfatídico (lpa) y el uso de los mismos.
CR20120158A (es) Compuestos de diòxido de iminotiadiazina como inhibidores de bace, composiciones y su uso.
NI201200023A (es) Derivados de 5-fluoropirimidinona
CR20120510A (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
CO6361927A2 (es) Quinazolinas para inhibicion de pdk1
ECSP11010798A (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
ECSP14013245A (es) Nuevos derivados dihidroquinolina-2-ona
PA8842101A1 (es) Heteroarilos sustituidos
CR20140071A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
BR112014015905A2 (pt) composição
DOP2017000202A (es) Desacetoxitubulisina h y análogos de esta
UY32077A (es) Inhibidores de quinasa tipo polo
MX2009012506A (es) Composiciones, sintesis, y metodos para utilizar agentes antipsicoticos atipicos basados en quinolinona.
NI201000023A (es) Derivados de indol-2-ona disustituidos en 3, su preparación y su aplicación en terapéutica.
CO6280532A2 (es) Derivados de isoquinolinona como antagonistas de nk3
CL2011000865A1 (es) Compuestos derivados de isoquinolinona; composicion farmaceutica que los comprende; y uso del compuesto para tratar enfermedades tales como psicosis, esquizofrenia, alzheimer entre otras.
CU20090161A7 (es) Pirimidinil-piperazinas útiles como ligandos del receptor d3/d2

Legal Events

Date Code Title Description
FC Application refused